Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. abopen

ABOPEN

FIRST INSTANT, OFF-THE-LAB AND USER-FRIENDLY BLOOD GROUPING TEST

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ABOPEN project word cloud

Explore the words cloud of the ABOPEN project. It provides you a very rough idea of what is the project "ABOPEN" about.

babies    urgent    attacks    transfusions    eldoncards    37c    pioneering    million    majority    rhd    turnover    hdnf    affordability    millions    roi    sizeable    red    2025    2002    prevented    procedure    eldon    performed    gynecology    curhe    countries    accuracy    kills    generate    world    similarly    obstretics    founding    disease    easily    works    24    stop    immune    company    keeping    mothers    months    pregnancy    figo    format    erase    eradicated    trained    rhesus    141    created    blood    pregnant    sold    moving    2    biologicals    dry    single    fetus    hemolytic    influential    personal    customers    tests    jobs    minute    despite    profitable    cells    device    hospitals    risk    women    accidents    tested    market    distributors    instant    overcoming    screening    newborn    laboratory    15    setting    mother    federation    hdfn    abopen    precision    electricity    regions    deaths    worldwide    children    network    stored    220    off    military    44    danish    outside    limitations    international    grouping    lab   

Project "ABOPEN" data sheet

The following table provides information about the project.

Coordinator		 ELDON BIOLOGICALS A/S 

Organization address
address: SANDTOFTEN 10
city: GENTOFTE
postcode: 2820
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Denmark [DK]
 Project website https://www.eldoncard.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELDON BIOLOGICALS A/S DK (GENTOFTE) coordinator 50˙000.00

Map

 Project objective

Despite being eradicated from the developed world, the Rhesus Disease or HDFN (Hemolytic Disease of the Fetus and Newborn), a disease where the immune system from the mother attacks the red blood cells from their babies, still kills 141,000 children and mothers in developing regions every year. Deaths that could be easily prevented by screening pregnant women for their RhD factor type. Although 15% of RhD(-) women are at risk, 220 million women in developing countries should be tested, since the majority do not know their RhD factor type. At Eldon Biologicals AS (a Danish company created in 2002), we are a profitable company that has already sold millions of EldonCards (a pioneering off-the-lab dry format grouping test) in more than 44 countries and has built a well-established worldwide network of customers and distributors. We are part of the influential International Federation of Gynecology and Obstretics (FIGO) and founding member of CURhE, an international initiative to stop HDNF. Now, we are moving one step further from EldonCards overcoming its limitations to erase HDNF from developing countries. To do so, we have created ABOPEN, a user-friendly off-the-lab grouping test that can be stored for up to 24 months at 37C and works similarly to pregnancy tests, identifying the RhD factor type in just 1 minute and a single-step procedure. ABOPEN can be performed outside a laboratory setting (does not need electricity) by non-trained personnel, while keeping its affordability (it costs just €4), precision and accuracy. ABOPEN has also a sizeable market in developed countries, as an instant and easy to use device to find out about blood grouping for urgent transfusions (accidents, hospitals, military) or just personal information. By end of 2025, we expect to generate €8 million in turnover (ROI of 2.2), while creating 7 new jobs for the company.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ABOPEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ABOPEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More